CIPLA Ltd. | Income Statement

Fiscal year is April-March. All values INR Millions.
2014
2015
2016
2017
2018
Sales/Revenue
97,994
109,508
134,420
142,298
150,110
Cost of Goods Sold (COGS) incl. D&A
62,584
68,839
87,991
94,062
97,336
Gross Income
35,410
40,668
46,429
48,236
52,774
SG&A Expense
20,275
27,636
29,987
32,663
34,618
EBIT
14,733
12,635
-
-
17,775
Unusual Expense
26
192
108
4,461
4,460
Non Operating Income/Expense
5,327
5,301
1,642
2,915
4,186
Interest Expense
1,457
1,683
2,066
1,594
1,142
Pretax Income
18,800
16,543
17,270
12,222
16,695
Income Tax
4,634
4,000
3,316
1,798
2,501
Equity in Affiliates
123
253
120
70
28
Consolidated Net Income
14,043
12,289
13,834
10,354
14,166
Net Income
13,884
11,808
13,600
10,064
14,105
Net Income After Extraordinaries
13,884
11,808
13,600
10,064
14,105
Net Income Available to Common
13,884
11,808
13,600
10,064
14,105
EPS (Basic)
17.29
14.71
16.93
12.52
17.53
Basic Shares Outstanding
803
803
803
804
805
EPS (Diluted)
17.27
14.66
16.89
12.50
17.50
Diluted Shares Outstanding
804
806
805
805
806
EBITDA
18,460
17,682
25,006
23,927
27,273
Other Operating Expense
402
397
1,022
361
381
Non-Operating Interest Income
171
98
99
125
296
Minority Interest Expense
159
482
234
290
60

About CIPLA

View Profile
Address
Cipla House, Peninsula Business Park
Mumbai Maharashtra 400013
India
Employees -
Website http://www.cipla.com
Updated 09/14/2018
Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. It operates through the Pharmaceuticals and New Ventures segments. The Pharmaceuticals segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients.